false
0000001750
0000001750
2025-12-01
2025-12-01
0000001750
us-gaap:CommonStockMember
exch:XCHI
2025-12-01
2025-12-01
0000001750
us-gaap:CommonStockMember
exch:XNYS
2025-12-01
2025-12-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
| Common Stock, $1.00 par value |
|
AIR |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 1, 2025
AAR
CORP.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
1-6263 |
|
36-2334820 |
(State or other jurisdiction
of incorporation ) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
One AAR Place
1100 N. Wood Dale Road
Wood Dale, Illinois |
60191 |
| (Address of principal executive offices) |
(Zip Code) |
| Registrant’s telephone number, including
area code: (630) 227-2000 |
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading Symbol(s) |
|
Name
of Each Exchange on Which Registered |
| Common
Stock, $1.00 par value |
|
AIR |
|
New
York Stock Exchange |
| |
|
NYSE Texas |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers. |
AAR CORP. (the “Company”)
is filing this amendment to the Company’s Current Report on Form 8-K dated December 4, 2025 (the “Original Form 8-K”),
which reported that the Company had appointed Sarah L. Flanagan, the Company’s Vice President, Financial Operations, to also serve
as the Company’s Interim Chief Financial Officer (“Interim CFO”) effective December 4, 2025. The Company is filing
this amendment to the Original Form 8-K to report certain compensation adjustments made to Ms. Flanagan’s compensation
in connection with her appointment as Interim CFO and Vice President, Financial Operations. There are no other changes to the information
contained in the Original Form 8-K.
Effective January 22,
2026, in connection with Ms. Flanagan’s appointment as Interim CFO and Vice President, Financial Operations, which was effective
December 4, 2025, the Human Capital and Compensation Committee of the Company’s Board of Directors approved adjustments to
Ms. Flanagan’s compensation in the form an increase to her long-term incentive award for the fiscal year ending May 31,
2026 (“Fiscal 2026”) previously granted on July 23, 2025. The increase was delivered in the form of new equity awards
together totaling approximately $500,000 in value based on the Company’s stock price at the close of trading on January 22,
2026 (the “Grant Date”). The awards were granted, in part, to recognize Ms. Flanagan for assuming the Interim CFO role
while the Company conducts a search for a permanent CFO, which includes consideration of internal and external candidates.
The equity awards that were
granted to Ms. Flanagan are comprised of 60% performance-based restricted stock, 20% time-based restricted stock, and 20% stock options,
as follows: (i) a grant of a number of shares of performance-based restricted stock (at target) with a grant date fair value of $107.74
per share based on the stock price at the close of trading on the Grant Date, with such performance-based restricted stock vesting in
full on the third-year anniversary of the Grant Date; (ii) a grant of a number of shares of time-based restricted stock with a grant
date fair value of $107.74 per share based on the stock price at the close of trading on the Grant Date, with such time-based restricted
stock vesting in full on the third-year anniversary of the Grant Date; and (iii) a grant of a number of stock options with an exercise
price of $107.74 per share based on the stock price at the close of trading on the Grant Date, with such stock options vesting in one-third
increments annually on the first-year, second-year, and third-year anniversaries of the Grant Date. For the grant of performance-based
restricted stock, the performance measures and the performance measurement period are the same as those under the Fiscal 2026 awards of
performance-based restricted stock that were granted to the Company’s executive officers on July 23, 2025, including a performance
measurement period comprised of the Company’s three fiscal years ending May 31, 2028.
The awards of performance-based
restricted stock, time-based restricted stock, and stock options were granted pursuant to and are subject to the terms and conditions
of the Company’s 2013 Stock Plan as amended and restated effective July 13, 2020 (reflecting amendments since July 13,
2020) (the “2013 Stock Plan”), and the Company’s Form of Fiscal 2026 Performance Restricted Stock Agreement, Form of
Fiscal 2026 Restricted Stock Agreement, and Form of Fiscal 2026 Non-Qualified Stock Option Agreement, respectively (except that the
grant dates, vesting dates, and option exercise price are different as set forth above). Ms. Flanagan’s annual base salary,
annual bonus opportunity, and long-term incentive opportunity were not adjusted in connection with her appointment as Interim CFO.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: January 23, 2026
| |
AAR CORP. |
| |
|
| |
By: |
/s/ Jessica A. Garascia |
| |
|
Jessica A. Garascia |
| |
|
Senior Vice President, General Counsel, Chief Administrative Officer and Secretary |